Xiamen Innovax Biotech Leads the Charge Against HPV at IPVS 2026

IX at IPVS 2026: Advancing Global HPV Prevention

In a significant display of commitment to global health, Xiamen Innovax Biotech Co., Ltd. (IX) participated in the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026) held in Athens, Greece, from October 22 to 25. This prestigious conference brought together experts and partners from around the world, focusing on the urgent need for innovative solutions in HPV prevention and cervical cancer elimination.

Listening to Global Voices

Under the theme "Together Against HPV," IX set up a dynamic presence at Booth 14, aiming to foster conversations about vaccine innovations and the critical need for accessibility in different healthcare environments. The booth featured an interactive signature board and message wall, inviting attendees to contribute their insights and commitments to HPV prevention. This initiative highlights IX’s dedication to understanding local public health contexts and translating scientific innovation into sustainable solutions.

A Platform for Innovation

During the conference, Dr. Nana A. Ansah from the Navrongo Health Research Centre in Ghana presented promising Month 6 interim data from PATH's Single-dose HPV Immunobridging Study (SHINE I; CVIA 104). This Phase III, double-blind, randomized multinational study examines the immunogenicity and safety of the single-dose Cecolin 9 in comparison to Gardasil 9, targeting girls aged 9–14 and young women aged 15–20. The anticipation surrounding final data, which is expected by 2028, underscores the importance of ongoing research and development in the HPV vaccine landscape.

Innovax’s Vaccine Portfolio

IX’s portfolio includes Cecolin, a WHO-prequalified bivalent HPV vaccine, and Cecolin 9, a next-generation 9-valent HPV vaccine launched in China in 2025. These vaccines are formulated using IX’s proprietary E. coli-derived virus-like particle (VLP) technology platform, ensuring that advancements in vaccine manufacturing meet international safety and efficacy standards. IX is continuously exploring ways to enhance vaccine accessibility through technology advancements and local partnerships.

Building Global Collaborations

IPVS 2026 serves as an important platform for IX to renew its commitment to the global HPV community. Through technology transfer and local capacity building, IX is addressing the need for sustainable vaccine supply and enhancing public health outcomes on a local level. The company's ongoing mission is to provide high-quality, affordable HPV vaccines, reinforcing its role as a leader in the fight against cervical cancer.

Conclusion

Xiamen Innovax Biotech’s active engagement at IPVS 2026 not only highlights the importance of listening to global voices in public health but also underscores the power of collaboration in advancing HPV prevention strategies. The company remains dedicated to its vision of eliminating cervical cancer through innovative and accessible vaccine solutions, demonstrating that with the right partnerships and commitment, significant progress can be made in global health efforts.